Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
G protein–coupled receptors (GPCRs) for glucagon (GluR) and glucagon-like peptide-1 (GLP-1R) are normally considered to be highly selective for glucagon and GLP-1, respectively. However, glucagon secreted from pancreatic α-cells may accumulate at high concentrations to exert promiscuous effects at the β-cell GLP-1R, as may occur in the volume-restricted microenvironment of the islets of Langerhans. Furthermore, systemic administration of GluR or GLP-1R agonists and antagonists at high doses may lead to off-target effects at other receptors. Here, we used molecular modeling to evaluate data derived from FRET assays that detect cAMP as a read-out for GluR and GLP-1R activation. This analysis established that glucagon is a nonconventional GLP-1R agonist, an effect inhibited by the GLP-1R orthosteric antagonist exendin(9–39) (Ex(9–39)). The GluR allosteric inhibitors LY2409021 and MK 0893 antagonized glucagon and GLP-1 action at the GLP-1R, whereas des-His 1 -[Glu 9 ]glucagon antagonized glucagon action at the GluR, while having minimal inhibitory action versus glucagon or GLP-1 at the GLP-1R. When testing Ex(9–39) in combination with des-His 1 -[Glu 9 ]glucagon in INS-1 832/13 cells, we validated a dual agonist action of glucagon at the GluR and GLP-1R. Hybrid peptide GGP817 containing glucagon fused to a fragment of peptide YY (PYY) acted as a triagonist at the GluR, GLP-1R, and neuropeptide Y2 receptor (NPY2R). Collectively, these findings provide a new triagonist strategy with which to target the GluR, GLP-1R, and NPY2R. They also provide an impetus to reevaluate prior studies in which GluR and GLP-1R agonists and antagonists were assumed not to exert promiscuous actions at other GPCRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“GLP-1 is also present within the nucleus solitarius of the brainstem (18), and it, too, participates in the suppression of appetite by binding to a diffuse network of GLP-1 receptors located within the central nervous system (19).”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · cited 12×
“Also note that GGP817 failed to exhibit agonist action at the GIP-R (Fig.”
BackgroundInfluentialRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Research works printed but not linked: 61
- Skow, 2016, Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins', Diabetes Obes. Metab, 18, 847, 10.1111/dom.12685 · DOI · Paper page
- Brandt, 2018, Gut hormone polyagonists for the treatment of type 2 diabetes, Peptides, 100, 190, 10.1016/j.peptides.2017.12.021 · DOI · Paper page
- Liapakis, 2017, Family B G protein-coupled receptors and their ligands: from structure to function, Curr. Med. Chem, 24, 3323, 10.2174/0929867324666170303162416 · doi:10.2174/0929867324666170303162416
- Parker, 2008, Neuropeptide Y Y2 receptor in health and disease, Br. J. Pharmacol, 153, 420, 10.1038/sj.bjp.0707445 · DOI
- Scott, 2018, Problem or solution: the strange story of glucagon, Peptides, 100, 36, 10.1016/j.peptides.2017.11.013 · DOI · Paper page
- Holz, 2003, Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus, Curr. Med. Chem, 10, 2471, 10.2174/0929867033456648 · DOI · Paper page
- Habib, 2013, Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells, Diabetologia, 56, 1413, 10.1007/s00125-013-2887-z · DOI · Paper page
- Wren, 2007, Gut hormones and appetite control, Gastroenterology, 132, 2116, 10.1053/j.gastro.2007.03.048 · DOI · Paper page
- Thorens, 1993, Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor, Diabetes, 42, 1678, 10.2337/diab.42.11.1678 · DOI · Paper page
- Runge, 2008, Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain, J. Biol. Chem, 283, 11340, 10.1074/jbc.M708740200 · DOI · Paper page
- Unson, 1987, Synthetic peptide antagonists of glucagon, Proc. Natl. Acad. Sci. U.S.A, 84, 4083, 10.1073/pnas.84.12.4083 · DOI
- Kazda, 2016, Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies, Diabetes Care, 39, 1241, 10.2337/dc15-1643 · DOI · Paper page
- Xiong, 2012, Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes, J. Med. Chem, 55, 6137, 10.1021/jm300579z · DOI · Paper page
- Jazayeri, 2016, Extra-helical binding site of a glucagon receptor antagonist, Nature, 533, 274, 10.1038/nature17414 · DOI · Paper page
- Chepurny, 2018, Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors, Sci. Rep, 8
- Klarenbeek, 2015, Fourth-generation Epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affinity, PLoS ONE, 10, 10.1371/journal.pone.0122513 · DOI · Paper page
- Dumont, 2000, BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist, Br. J. Pharmacol, 129, 1075, 10.1038/sj.bjp.0703162 · DOI
- Jelinek, 1993, Expression cloning and signaling properties of the rat glucagon receptor, Science, 259, 1614, 10.1126/science.8384375 · DOI · Paper page
- Gremlich, 1995, Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor, Diabetes, 44, 1202, 10.2337/diab.44.10.1202 · DOI · Paper page
- Cooper, 1997, An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells, Br. J. Pharmacol, 122, 546, 10.1038/sj.bjp.0701401 · DOI
- Hohmeier, 2000, Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion, Diabetes, 49, 424, 10.2337/diabetes.49.3.424 · DOI · Paper page
- Zhang, 2017, Structure of the full-length glucagon class B G-protein-coupled receptor, Nature, 546, 259, 10.1038/nature22363 · DOI · Paper page
- Wootten, 2013, Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations, Proc. Natl. Acad. Sci. U.S.A, 110, 5211, 10.1073/pnas.1221585110 · DOI · Paper page
- Underwood, 2010, Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor, J. Biol. Chem, 285, 723, 10.1074/jbc.M109.033829 · DOI · Paper page
- Zhang, 2017, Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein, Nature, 546, 248, 10.1038/nature22394 · DOI · Paper page
- Zhang, 2018, Structure of the glucagon receptor in complex with a glucagon analogue, Nature, 553, 106, 10.1038/nature25153 · DOI
- Chabenne, 2014, A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia, Mol. Metabol, 3, 293, 10.1016/j.molmet.2014.01.006 · DOI
- Liang, 2018, Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex, Nature, 555, 121, 10.1038/nature25773 · DOI · Paper page
- Xiao, 2000, Characterization of glucagon-like peptide-1 receptor-binding determinants, J. Mol. Endocrinol, 25, 321, 10.1677/jme.0.0250321 · DOI · Paper page
- Dong, 2008, Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors, Mol. Endocrinol, 22, 1489, 10.1210/me.2008-0025 · DOI
- Moens, 1998, Dual glucagon recognition by pancreatic β-cells via glucagon and glucagon-like peptide-1 receptors, Diabetes, 47, 66, 10.2337/diab.47.1.66 · DOI · Paper page
- Nie, 2000, Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats, J. Clin. Invest, 105, 955, 10.1172/JCI7456 · DOI · Paper page
- Whalley, 2011, Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells?, J. Endocrinol, 211, 99, 10.1530/JOE-11-0094 · DOI · Paper page
- Marchetti, 2012, A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets, Diabetologia, 55, 3262, 10.1007/s00125-012-2716-9 · DOI · Paper page
- Donath, 2013, GLP-1 effects on islets: hormonal, neuronal, or paracrine?, Diabetes Care, 36, S145, 10.2337/dcS13-2015 · DOI · Paper page
- O'Malley, 2014, Progressive change of intra-islet GLP-1 production during diabetes development, Diabetes Metab. Res. Rev, 30, 661, 10.1002/dmrr.2534 · DOI · Paper page
- Svendsen, 2018, Insulin secretion depends on intra-islet glucagon signaling, Cell Rep, 25, 1127, 10.1016/j.celrep.2018.10.018 · DOI · Paper page
- Kawai, 1995, Evidence that glucagon stimulates insulin secretion through its own receptor in rats, Diabetologia, 38, 274, 10.1007/BF00400630 · DOI
- Serre, 1998, Exendin-(9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence, Endocrinology, 139, 4448, 10.1210/endo.139.11.6295 · DOI · Paper page
- Rose, 1995, Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor, J. Biol. Chem, 270, 22661, 10.1074/jbc.270.39.22661 · DOI · Paper page
- Holz, 1992, Signal transduction crosstalk in the endocrine system: pancreatic beta-cells and the glucose competence concept, Trends Biochem. Sci, 17, 388, 10.1016/0968-0004(92)90006-U · DOI
- Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37), Nature, 361, 362, 10.1038/361362a0 · DOI · Paper page
- Chepurny, 2002, Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220, Endocrinology, 143, 2303, 10.1210/endo.143.6.8870 · doi:10.1210/endo.143.6.8870 · Paper page
- Holz, 2004, New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells, Horm. Metab. Res, 36, 787, 10.1055/s-2004-826165 · DOI · Paper page
- Holz, 2005, Diabetes outfoxed by GLP-1?, Sci. STKE, 2005, pe2, 10.1126/stke.2682005pe2 · DOI · Paper page
- Leech, 2011, Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic beta cells, Prog. Biophys. Mol. Biol, 107, 236, 10.1016/j.pbiomolbio.2011.07.005 · DOI · Paper page
- Calabria, 2012, GLP-1 receptor antagonist exendin-(9–39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel, Diabetes, 61, 2585, 10.2337/db12-0166 · DOI · Paper page
- Sathananthan, 2013, Direct effects of exendin-(9,39) and GLP-1-(9–36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects, Diabetes, 62, 2752, 10.2337/db13-0140 · DOI · Paper page
- Chambers, 2017, The role of pancreatic preproglucagon in glucose homeostasis in mice, Cell Metab, 25, 927, 10.1016/j.cmet.2017.02.008 · DOI · Paper page
- Karageorgos, 2018, Current understanding of the structure and function of family B GPCRs to design novel drugs, Hormones (Athens), 17, 45, 10.1007/s42000-018-0009-5 · DOI
- Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM), Diabetes, 60, A85
- Kjaergaard, 2019, PYY(3–36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice, Neuropeptides, 73, 89, 10.1016/j.npep.2018.11.004 · DOI
- Gromada, 1995, Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release, FEBS Lett, 373, 182, 10.1016/0014-5793(95)01070-U · DOI · Paper page
- Jiang, 2001, Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase, Proc. Natl. Acad. Sci. U.S.A, 98, 10102, 10.1073/pnas.131200398 · DOI · Paper page
- Kim, 2005, A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis, J. Biol. Chem, 280, 28692, 10.1074/jbc.M504913200 · DOI · Paper page
- Chepurny, 2007, A novel cyclic adenosine monophosphate responsive luciferase reporter incorporating a nonpalindromic cyclic adenosine monophosphate response element provides optimal performance for use in G protein coupled receptor drug discovery efforts, J. Biomol. Screen, 12, 740, 10.1177/1087057107301856 · DOI
- Allen, 2006, Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters, Biochem. Biophys. Res. Commun, 348, 716, 10.1016/j.bbrc.2006.07.136 · DOI · Paper page
- Chepurny, 2009, Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2′-O-Me-cAMP-AM, J. Biol. Chem, 284, 10728, 10.1074/jbc.M900166200 · DOI · Paper page
- Schwede, 2015, Rp-cAMPS prodrugs reveal the cAMP dependence of first-phase glucose-stimulated insulin secretion, Mol. Endocrinol, 29, 988, 10.1210/me.2014-1330 · DOI
- Koebel, 2016, S...O and S...N sulfur bonding interactions in protein-ligand complexes: empirical considerations and scoring function, J. Chem. Inf. Model, 56, 2298, 10.1021/acs.jcim.6b00236 · DOI
- Trott, 2010, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem, 31, 455, 10.1002/jcc.21334 · DOI · Paper page
Cited by
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“For example, LY2409021, originally developed as a GCGR antagonist, was subsequently found to block the actions of glucagon at the GCGR and GLP-1R, the actions of GLP-1 at the GLP-1R, and the actions of GIP at the GIPR in vitro.(139)”
BackgroundGLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Self-citationUpdating the Role of α-Cell Preproglucagon products on GLP-1 receptor–mediated insulin secretion
Sandoval, D. (2020) · Diabetes · doi:10.2337/dbi19-0027 · Cited by 12
Metadata
- Authors
- Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 294
- Issue
- 10
- Pages
- 3514-3531
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2909281962
- Cited by
- 41
- References
- 18
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Update notices
- erratum (2019-05-31)
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 544 d)
- Funders
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK069575)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. https://app.cochat.ai/papers/10.1074/jbc.ra118.005682
- The paper
- Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019). Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.ra118.005682
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.